Friday, February 10, 2023, 2:11 p.m.
Open US Clinical Research new anti-covid drug One injection can defeat all species.
February 10, 2023 Medical Genome Center Faculty of Medicine Ramathibodi Hospital Mahidol University Information posted via Facebook Center for Medical Genomics has the following content…
New drug hopes for treating COVID-19 A clinical study in the United States found that a single “injection” significantly reduced severe illness and death from all strains of the novel coronavirus 2019. It has a broad spectrum antiviral activity and may be used to combat other respiratory and gastrointestinal diseases in the future.
A clinical study by a US research team, reported Feb. 9, 2023 in “The New England Journal of Medicine,” concluded that patients with COVID-19 are at high risk of developing severe symptoms. A single subcutaneous injection of pegylated interferon lambda has been reported. There was a “less risk” of being hospitalized within 28 days (post-treatment) compared to the placebo group.
Peglated Interferon It combines polyethylene glycol (PEG) with an interferon molecule. The addition of PEG allows for a slow release of interferon from the injection site.
interferon lambda It only binds to receptors on the surface of epithelial cells, such as those in the lungs, respiratory tract and intestines, where the 2019-nCoV primarily binds and acts. including the liver Researchers speculate that this is why interferon lambda has the least side effects. This is not surprising, as interferon lambda has been safely used in more than 3,000 patients in clinical trials for the treatment of hepatitis.
Volunteers participating in the project received injections of peglated interferon lambda, or PEG-lambda (PEG-lambda), within “one week” of showing symptoms of COVID-19. found that those who received PEG-lambda early is within the first three days of symptoms The most benefited: A 65% reduction in risk of hospitalization in the next month was found among these volunteers. The risk of hospitalization was reduced by 89% compared to placebo.
In the case of the antiretroviral drug Paxlovid, it reduced the risk of hospitalization among unvaccinated people by 89%, according to the final trial that helped the drug. It has received Emergency Use (EUA) approval from the US Food and Drug Administration (FDA). However, one key difference between PEG-lambda and Paxlovid is that PEG-lambda is Although Paxlovid is a single injection, Paxlovid is prescribed to take 3 tablets twice a day for 5 days, for a total of 30 tablets.
Therefore, the drug PEG-Lambda is easy for patients to be 100% compliance (100% compliance) due to a single injection.
While Paxlovid is aimed at inhibiting the novel coronavirus 2019, PEG-lambda theoretically increases the immune system’s first line of defense against multiple pathogens non-specifically. And it doesn’t appear to induce the virus to mutate or become drug resistant like using conventional antiviral drugs.
PEG-Lambda has been proven effective in inhibiting the multiplication of all 2019-CoV-2 strains including Omikron. No matter how the spike protein changes which is different from vaccination and the injection of monoclonal antibodies to enhance the immune system, which is ineffective when the virus is mutated and changes the spindle protein.
PEG-lambda is a synthetic mimetic protein of the lambda interferon. It is a human-made protein naturally secreted by white blood cells when invaded by a virus. Interferon proteins interfere with the multiplication of virtually all viruses that invade the cell. In addition, interferon proteins signal to neighboring cells that the virus has invaded the body. triggering a chain of immune responses
Interferon is a natural human antiviral drug that inhibits broad spectrum viral replication, the body’s first line of defense against viral threats. regardless of how the virus mutates.
The PEG-lambda research was originally focused primarily on the treatment of viral hepatitis. But from laboratory experiments, it has been shown to have the potential to fight against the novel coronavirus 2019 as well.
which is the origin of this clinical trial This relies on nearly 2,000 new COVID-19 cases admitted to 12 health facilities in Brazil and five in Canada between June 2021 and February 2022.
The results were satisfactory within seven days after the onset of symptoms of an infected person. Patients were randomized to receive a single injection of PEG-lambda or placebo. Less than 3% of patients receiving PEG-lambda required hospitalization. This compares with nearly 6% of people who received a placebo. That represented a 51% reduction in the risk of hospitalization for those receiving PEG-lambda.
The results were even better when patients were treated with PEG-lambda within three days — just 1.9% of hospitalizations compared to 3.1% in the placebo group. This means that the risk can be reduced by 58%.
The following side effects from PEG-lambda use were reported to be minimal. It was not possible to distinguish which subjects received PEG-lambda and which received placebo. The conclusion is that there are “not different side effects”
“Safety” is a concern when using it. Interferon is known as interferon because it is known to trigger a dangerous and potentially fatal cytokine storm.
For example, interferon alpha. alfa-interferon, which has been used to treat hepatitis C and cancer It was found to be toxic to various organ systems due to interferon alpha It can bind to a wide variety of cells in the body, unlike PEG-lambda, which only binds to cells in the respiratory and gastrointestinal tract. Does not induce hyper-immune reactions in other tissue types including muscle tissue or immune cells
The results of this project were able to confirm the effectiveness of PEG-lambda against COVID-19. It also indicates whether the drug is also effective against influenza virus or RSV (respiratory syncytial virus).
PEG-Lambda is currently under review by the US Food and Drug Administration. It is expected that it will soon be widely used in hospitals.
For Thailand, we have herbs such as “Fah Talai Rob” is another interesting alternative to reduce the severity of COVID-19.
Early Treatment with Pegylated Interferon Lambda for Covid-19
https://www.nejm.org/doi/full/10.1056/NEJMoa2209760…
-005
